Represented Madrigal Pharmaceuticals (NasdaqGM: MDGL) in connection with its $35 million private placement offering, consisting of 1.97 million shares of Series A Convertible Preffered Stock and 328,300 shares of common stock. Investors included existing, non-controlling stockholders of Madrigal. The company expects to use the funds to continue its clinical studies for MGL-3196, a proprietary, liver-directed, selective thyroid hormone receptor- ß, for the treatment of non-alcoholic steatohepatitis (NASH), and for the development of other product candidates.
Represented Santen Pharmaceuticals, Co., Ltd. of Osaka, Japan in connection with a strategic investment in Regenerative Patch Technologies, LLC, an early stage company located in the Bay Area, which is developing stem cell therapies for treatment of retinal diseases.
Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) with its license and related supply agreements with Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) for drug formulation with ganaxolone. Under the agreement, Ligand will receive an upfront payment and is entitled to receive potential milestone payments, royalties and revenue from future sales of Captisol-enabled ganaxolone.
Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in connection with its worldwide OmniAb Platform License Agreement with bluebird bio, Inc. (NASDAQ: BLUE) for antibody development. Under the agreement, Ligand is eligible to receive annual platform access payments, development milestone payments and royalties for each product that incorporates an OmniAb antibody.
Represented Ansun Biopharma Inc. in connection with its Convertible Note Financing. Ansun Biopharma is a clinical stage biopharmaceutical company that focuses on developing unique host-directed anti-viral therapies for respiratory viruses.
Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in its license and supply agreements with Novartis for the development and global commercialization of Captisol-enabled trametinib. Under the agreement, Ligand is eligible to receive a license fee, royalty payments on future net sales, and revenue from Captisol sales.
Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in its worldwide OmniAb platform license agreement with ONO PHARMACEUTICAL CO., LTD. Under the license, ONO will be able to use the OmniRat, OmniMouse and OmniFlic platforms for antibody development.
Represented Abimmune Biopharma Inc. in connection with its Convertible Note Financing. Abimmune Biopharma is a startup company that focuses on generating novel nanobody based drug candidates against a wide spectrum of high-value immunomodulatory and oncology targets related to T lymphocytes, solid tumors, and tumor stem cells.
Represented Integrated Prescription Solutions, Inc. in its sale to Mitchell International, Inc. of substantially all of its assets for an undisclosed price, pursuant to a previously executed agreement with Mitchell International, Inc.
Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in its strategic alliance with Seelos Therapeutics, licensing them the rights to four therapeutic programs. The programs include Ligand’s aplindore program for the treatment of central nervous system disorders, a CRTH2 antagonist program for the treatment of respiratory disorders, a Captisol-enabled acetaminophen program for pain and fever management, and an H3 receptor antagonist program for the treatment of narcolepsy. Under the agreement, Ligand can receive up to $145 million milestone payments, plus royalties.
On September 19, 2016, Stradling client Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced an exclusive worldwide license agreement providing Tarveda Therapeutics, Inc. rights for the discovery, development and commercialization by Tarveda of products based on Madrigal’s HSP90 Drug Conjugate program, including the lead clinical candidate, PEN-866.
Represented Vala Sciences, Inc. in connection with its Convertible Note Financing. Vala Sciences is a San diego-based biotechnology company that focuses on developing and commercializing cell-image-based instrumentation, reagents and analysis software tools for academic, pharmaceutical and biotechnology scientists.
Represented Madrigal Pharmaceuticals, Inc. in its merger with Synta Pharmaceuticals Corp.